UGT1A1 and metabolic dysfunction-associated steatotic liver disease: However, in a group of 56 subjects diagnosed with either HCV or non-alcoholic fatty liver disease (NAFLD), mutant allele UGT1A1*28 produced little inter-subject variability in silybin pharmacokinetics [30].